Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma

Porubsky, S; Jessup, P; Kee, D; Sharma, R; OCHI, A; Xu, H; Froelich, JJ; Nott, L; Scott, C; Awad, R; Moldovan, C; Hardikar, AA; Bohnenberger, H; Kuffer, S; Strobel, P; Marx, A

Author(s): Porubsky, S; Jessup, P; Kee, D; Sharma, R; OCHI, A; Xu, H; Froelich, JJ; Nott, L; Scott, C; Awad, R; Moldovan, C; Hardikar, AA; Bohnenberger, H; Kuffer, S; Strobel, P; Marx, A;
Details: Publication Year 2020-02,Volume 476,Issue #2,Page 323-327
Journal Title: Virchows Archiv
Publication Type: Journal Article
Abstract: Our aim was to investigate sebaceous differentiation in thymus tumours and to identify new actionable genomic alterations. To this end we screened 35 normal and 23 hyperplastic thymuses, 127 thymomas and 41 thymic carcinomas for the presence of sebaceous differentiation as defined by morphology and expression of adipophilin and androgen receptor (AR). One primary thymic carcinoma showed morphology of sebaceous carcinomas (keratinizing and foam cells, calcifications, giant cells), a strong expression of adipophilin and AR together with squamous markers. NGS revealed high-level amplification of fibroblast growth factor receptor 2 (FGFR2). In thymuses and thymomas, no cells with sebaceous morphology were present. Occasionally, macrophages or epithelial cells showed adipophilin-positivity, however, without co-expression of AR. Thymic sebaceous carcinoma should be considered if a thymic carcinoma shows clear or foamy features. Testing for FGFR2 amplification might be warranted when searching for actionable genomic alterations in sebaceous carcinomas in the mediastinum and in other locations.
Publisher: Springer
Research Division(s): Cancer Biology And Stem Cells
PubMed ID: 31401665
Publisher's Version: https://doi.org/10.1007/s00428-019-02644-3
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2019-08-13 12:35:08

Last Modified: 2020-04-02 02:16:17